Rapid triaging, treatment response assessment and outcome prediction in COVID-19 patients

点击翻译按钮获取中文摘要

In healthcare, timely and personalised interventions have a crucial role in the ultimate effectiveness of both current and future treatments for a wide range of diseases. This is also true for COVID-19, where early detection would result in a significantly improved patient prognosis. AINOSTICS' technology represents a breakthrough that would provide an automated, extensible, and personalised healthcare platform for assisting the clinical diagnosis and management of patients suffering from COVID-19, using multi-modal clinical imaging and non-imaging data; useful for both the treatment of patients, and importantly, in the development of novel therapeutics.We intend for AINOSTICS' software to become a routine part of clinical practice and drug development as the results of our intelligent analysis will provide clinicians, researchers, and imaging centres a convenient and cost-effective means to get reliable, quantitative and objective diagnostic data.For serious global diseases, AINOSTICS' technology has the potential to save time during patient assessments, accelerate clinical pathways, standardise the quality of care and improve patient outcomes, in addition to making important contributions to the development of disease modifying therapeutics.